Literature DB >> 15338762

Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.

E Tiensuu Janson1, Kjell Oberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 15338762

Source DB:  PubMed          Journal:  Cancer Chemother Biol Response Modif        ISSN： 0921-4410


× No keyword cloud information.
  9 in total

1.  Treatment of neuroendocrine tumors with somatostatin analogs.

Authors:  Eva Tiensuu Janson
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 2.  Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.

Authors:  Marialuisa Appetecchia; Roberto Baldelli
Journal:  J Exp Clin Cancer Res       Date:  2010-03-02

Review 3.  Medical treatment for gastro-entero-pancreatic neuroendocrine tumours.

Authors:  Rossana Berardi; Francesca Morgese; Mariangela Torniai; Agnese Savini; Stefano Partelli; Silvia Rinaldi; Miriam Caramanti; Consuelo Ferrini; Massimo Falconi; Stefano Cascinu
Journal:  World J Gastrointest Oncol       Date:  2016-04-15

4.  Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease.

Authors:  M Pulcrano; L Camera; L Pagano; S Del Vecchio; D Ferone; L Bodei; A Murgia; L Pace; G Storto; G Paganelli; A Colao; M Salvatore; G Lombardi; B Biondi
Journal:  J Endocrinol Invest       Date:  2008-04       Impact factor: 4.256

5.  Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas - predominance of receptor subtype 4.

Authors:  Guida Maria Portela-Gomes; Mats Stridsberg; Lars Grimelius; Otto Rorstad; Eva Tiensuu Janson
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

6.  Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors.

Authors:  A Faggiano; G Mansueto; P Ferolla; F Milone; M L del Basso de Caro; G Lombardi; A Colao; G De Rosa
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

7.  Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.

Authors:  Claudia Pivonello; Panagoula Rousaki; Mariarosaria Negri; Maddalena Sarnataro; Maria Napolitano; Federica Zito Marino; Roberta Patalano; Maria Cristina De Martino; Concetta Sciammarella; Antongiulio Faggiano; Gaetano Rocco; Renato Franco; Gregory A Kaltsas; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

8.  Ectopic Cushing' syndrome caused by a neuroendocrine carcinoma of the mesentery.

Authors:  Mathias Fasshauer; Thomas Lincke; Helmut Witzigmann; Regine Kluge; Andrea Tannapfel; Michael Moche; Michael Buchfelder; Stephan Petersenn; Juergen Kratzsch; Ralf Paschke; Christian A Koch
Journal:  BMC Cancer       Date:  2006-04-27       Impact factor: 4.430

Review 9.  Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.

Authors:  Roberto Baldelli; A Barnabei; L Rizza; A M Isidori; F Rota; P Di Giacinto; A Paoloni; F Torino; S M Corsello; A Lenzi; M Appetecchia
Journal:  Front Endocrinol (Lausanne)       Date:  2014-02-07       Impact factor: 5.555
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.